It is obvious that the results published so far as well as the present preliminary data do not answer many questions regarding the optimal therapeutic regimen in GH deficiency. In particular, long-term follow-up must be organized to evaluate efficacy and safety of GH therapy not only in GHD but also for the "new" indications such as Turner syndrome, short stature without classical GH deficiency and chronic renal failure. Finally the high expectations and the high costs of longterm GH treatment should receive full consideration.